Welcome to our dedicated page for Atricure SEC filings (Ticker: ATRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Device approvals, clinical-trial results, and insider trades all live inside AtriCure’s SEC paperwork—but they are hard to spot. Medical-device disclosures run hundreds of pages, packed with FDA language, trial endpoints, and revenue splits between ablation and cryotherapy systems. If you have ever searched for recall language or the latest CryoICE sales trend inside an annual report, you know the challenge.
Stock Titan solves that problem. Our platform delivers AtriCure SEC filings explained simply: AI-powered summaries highlight what changed, why it matters, and where to find detail. Whether you need the AtriCure annual report 10-K simplified for pipeline updates, the AtriCure quarterly earnings report 10-Q filing to compare segment growth, or an AtriCure 8-K material events explained alert on new FDA clearances, we surface it the moment EDGAR publishes. Real-time monitors flag AtriCure Form 4 insider transactions real-time, helping you track AtriCure executive stock transactions Form 4 before markets open. Interactive tables let you drill into cash‐flow swings, R&D spending, and risk-factor revisions—no manual page dives required.
Professionals use these insights to:
- Follow AtriCure insider trading Form 4 transactions ahead of earnings calls
- Compare ablation versus LAA device revenue across quarters with our AtriCure earnings report filing analysis
- Review AtriCure proxy statement executive compensation when evaluating governance
Nuwellis, Inc. (NASDAQ: NUWE) has filed an 8-K detailing two material corporate actions:
1. Leadership change (Item 5.02): The Board appointed long-time director and chairman John L. Erb (age 76) as permanent Chief Executive Officer and President effective 27 Jun 2025. His 12-month employment agreement provides:
- Annual base salary: $431,097 (effective 20 May 2025, subject to annual review)
- Target annual bonus: 65 % of base salary
- Equity grant: 115,329 stock options vesting monthly over 12 months under the 2017 Equity Incentive Plan
2. Reverse stock split (Item 5.03 / 3.03): Following prior shareholder approval, the Board approved a 1-for-42 reverse split of issued and outstanding common shares. Key details:
- Effective time: 5:00 p.m. ET, 3 Jul 2025; split-adjusted trading begins 7 Jul 2025
- No change to par value; proportional adjustment to all equity-linked securities and plan reserves
- Fractional shares: rounded down; cash paid at last pre-split Nasdaq close
- Ticker unchanged (NUWE); new CUSIP: 67113Y702; Equiniti Trust Company will act as exchange agent
The filing also lists Exhibits 3.1 (Certificate of Amendment) and 10.1 (Employment Agreement).
On 30 June 2025, AtriCure, Inc. (ATRC) Chief Legal Officer Karl S. Dahlquist acquired 822 common shares through the company’s 2018 Employee Stock Purchase Plan (ESPP). The purchase price was $25.84, reflecting the plan’s 15% discount from the closing price of $30.40 on 2 January 2025, the first trading day of the offering period. Following the transaction, Dahlquist directly owns 68,551 ATRC shares. The Form 4 was signed on 2 July 2025 and indicates a routine, plan-based acquisition with no shares sold or disposed of.
On 30 June 2025, AtriCure, Inc. (ATRC) Chief Legal Officer Karl S. Dahlquist acquired 822 common shares through the company’s 2018 Employee Stock Purchase Plan (ESPP). The purchase price was $25.84, reflecting the plan’s 15% discount from the closing price of $30.40 on 2 January 2025, the first trading day of the offering period. Following the transaction, Dahlquist directly owns 68,551 ATRC shares. The Form 4 was signed on 2 July 2025 and indicates a routine, plan-based acquisition with no shares sold or disposed of.
On 30 June 2025, AtriCure, Inc. (ATRC) Chief Legal Officer Karl S. Dahlquist acquired 822 common shares through the company’s 2018 Employee Stock Purchase Plan (ESPP). The purchase price was $25.84, reflecting the plan’s 15% discount from the closing price of $30.40 on 2 January 2025, the first trading day of the offering period. Following the transaction, Dahlquist directly owns 68,551 ATRC shares. The Form 4 was signed on 2 July 2025 and indicates a routine, plan-based acquisition with no shares sold or disposed of.
On 30 June 2025, AtriCure, Inc. (ATRC) Chief Legal Officer Karl S. Dahlquist acquired 822 common shares through the company’s 2018 Employee Stock Purchase Plan (ESPP). The purchase price was $25.84, reflecting the plan’s 15% discount from the closing price of $30.40 on 2 January 2025, the first trading day of the offering period. Following the transaction, Dahlquist directly owns 68,551 ATRC shares. The Form 4 was signed on 2 July 2025 and indicates a routine, plan-based acquisition with no shares sold or disposed of.
FAQ
What is the current stock price of Atricure (ATRC)?
What is the market cap of Atricure (ATRC)?
What is AtriCure's core business?
What types of technologies does AtriCure offer?
How does AtriCure improve atrial fibrillation treatment?
What is the significance of AtriCure's left atrial appendage management solutions?
How does AtriCure support minimally invasive surgical procedures?
Through which channels does AtriCure distribute its products?
Who are the primary users of AtriCure's technologies?
What differentiates AtriCure from other companies in the medical device industry?
